From: HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study
 |  | All samplesa | Archived DNA | Frozen tissue | FFPE tissue |
---|---|---|---|---|---|
Cervical samplesb | 128 (incl. 7 frozen-FFPE and 3 DNA-frozen tumor-tumor pairs) | 28 | 44 (incl. 4 tumor-normal pairs) | 56 (incl. 2 tumor-tumor pairs) | |
Additional samples | 7 | 6 (prostate) | 0 | 1 (vaginal tissue) | |
Samples with L1 amplicon sequencing | 135 | 34 | 44 | 57 | |
Number of samples with QC array data | 70 | 26 | 44 | 0 | |
Collection year (Mean ± SD) | 1999 ± 11 | Not reported | 1995 ± 11 | 2003 ± 9 | |
Age (Mean ± SD) | 51.4 ± 14.9 | Not reported | 51.6 ± 15.5 | 50.83 ± 14.7 | |
Histological subtype | Adenocarcinoma (AC) | 25 | 3 | 9 | 13 |
Adenosquamous Carcinoma (ASC) | 6 | 1 | 0 | 5 | |
Squamous Cell Carcinoma (SSC) | 87 | 23 | 27 | 37 | |
Other | 3 | 1 | 1 | 1 | |
Not reported/ not applicable | 14 | 6 | 7 | 1 | |
Reported racec | Asian | 11 | Not reported | 1 | 10 |
Black | 4 | 2 | 2 | ||
Other | 4 | 2 | 2 | ||
White/caucasian | 70 | 27 | 43 | ||
ADMIXTURE-predicted super-population assignmentd | African (AFR) | 4 | 0 | 4 | Not processed |
Admixed American (AMR) | 23 | 3 | 20 | ||
East Asian (EAS) | 4 | 2 | 2 | ||
European (EUR) | 27 | 16 | 11 | ||
South Asian (SAS) | 0 | 0 | 0 | ||
AMR/EUR | 7 | 1 | 6 | ||
AFR/EUR | 1 | 1 | 0 | ||
SAS/EUR | 1 | 0 | 1 |